Dr Goss presents at ASCO 2016, a Randomised Phase III Open Label Trial which looked at extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
Read the news story for more.